BeStock  
Stocks › Medical Devices › PACB

Pacific Biosciences of California PACB

US equityMarket cap rank #3575Medical Devices
$1.63 −$0.13 (-7.39%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $1.63 +0.28%
Open$1.69
Prev close$1.76
Day range$1.61 – $1.73
Volume13.69M
Market cap$510.07M
P/E (TTM)–
Dividend yield–

PACB Stock News

Headlines matching Pacific Biosciences of California or the PACB ticker, most recent first.

  • CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy RatingMarket news · 11 Sep 2026 · Direct mention
  • Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2Market news · 6 Aug 2026 · Direct mention
  • TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3Market news · 6 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)TipRanks · 6 Aug 2026 · Direct mention
  • CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3Market news · 17 Aug 2026 · Direct mention
  • Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX) PositiveTipRanks · 9 May 2026 · Direct mention
  • Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1 NegativeMarket news · 14 Apr 2026 · Direct mention
  • Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2 PositiveMarket news · 13 Feb 2026 · Direct mention
  • UBS Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2.7Market news · 9 Nov 2026 · Direct mention
  • CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Announces Target Price $3Market news · 6 Nov 2026 · Direct mention
  • Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $3 PositiveMarket news · 5 Nov 2026 · Direct mention
  • Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Raises Target Price to $2 PositiveMarket news · 5 Nov 2026 · Direct mention
  • Earnings Flash (PACB) Pacific Biosciences of California, Inc. Posts Q3 Adjusted Loss $0.11 per Share, Vs. FactSet Est of $-0.13 NegativeMT Newswires · 5 Nov 2026 · Direct mention
  • Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25Market news · 7 Oct 2026 · Direct mention
  • Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $2.5 PositiveMarket news · 23 Oct 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on PACB.

Sign in to join the discussion.

Scroll to Top